As bodybuilders, we can benefit greatly from this increased bone strength by having them support growing muscles and support the regular lifting of heavy weights. With the increase in growth hormone comes the ability to gain more muscle faster. However, once you understand how growth hormones work and their benefits to the body, you see how MK-677 gains powerful benefits. Its main power lies in its ability to boost growth hormone and insulin-like growth factor 1 (IGF-1), which has several significant benefits for bodybuilders and athletes. It is used for muscle building, anti-aging purposes, improving bone density, and treating conditions like growth hormone deficiency and muscle wasting (in research settings). It promotes muscle growth, improves sleep quality, enhances fat metabolism, and supports recovery by increasing GH and IGF-1 levels. While the authors found that total body fat was unchanged as previously observed, the mean total body fat decreased by a non-significant 0.2 kg at 2 weeks and 0.4 kg at 8 weeks compared to baseline. The ibutamoren treatment group experienced a significant weight gain of 2.7 kg at 8 weeks, which decreased to a nonsignificant 1.8 kg weight gain 1 week after the end of treatment. Paralleling the Chapman et al. study, ibutamoren led to an elevation in serum prolactin at 2 and 8 weeks but no significant changes were observed in serum or urine cortisol. These ibutamoren treatments boosted pulsatile GH release yielding a 1.7-fold increase in GH secretion over 24 h. When compared to baseline, both 10 and 25 mg ibutamoren doses increased the mean 24-h GH concentration by 57% and 97%, respectively. To summarise, there is preliminary evidence that taking MK-677, a growth hormone secretagogue, could reduce testosterone levels in men. Insufficient testosterone can affect not only sexual development but also growth, bone mineral density, bone health, lean muscle and skin elasticity. In a study involving healthy older men at risk of age-related testosterone reductions, testosterone supplementation increased GH and IGF-I concentrations . Both studies showed increased appetite scores at baseline when 1 mcg/kg/hr of GHRP-2 was administered when compared with placebo(44, 45). Ibutamoren mesylate has also been used in the setting of GH deficient children, but not as extensively as the GHRPs, with a single study demonstrating increases in GH and IGF-1 levels after only 7 days of therapy, without examining growth rates(43). Six of 15 patients remained on treatment for 18–24 months and continued to see an average increased growth velocity of 6.0±0.4 cm/year(42). A third study evaluating GHRP-2 in doses of 5–15 mcg/kg two or three times per day in 15 children with short stature further confirmed the previously observed increases in growth velocity following treatment. A subsequent study examined the effects of GHRP-2 in 10 prepubertal children with growth deficiency, showing that while GHRP-2 appears to have a transient stimulatory effect on appetite, it does not lead to a durable increase in BMI(40). MK-677 can boost high levels of GH in the bloodstream by stimulating growth hormone release from the pituitary gland. If you’re looking to increase your muscle growth without affecting your testosterone, MK-677 is a potent option. It boosts growth hormone levels with little to no effect on other hormones, such as cortisol, which can suppress the function of the immune system, brain, and memory. MK-677, also known as ibutamoren or ibutamoren mesylate, is a peptide that belongs to the growth hormone secretagogues group (GHSR). This means it signals the body to secrete more of its own growth hormone. At 2 weeks, serum leptin levels were increased with ipamorelin compared to saline-treated controls and an increase in cumulative food intake during the first week. DEXA scans in GH-intact mice revealed that ipamorelin increased total body fat percentages compared to saline-treated controls while GH had no effect. Adunsky et al. reported four patients on ibutamoren (6.5%) with elevated blood glucose, compared with one patient on placebo (1.7%). Across the three trials, only two subjects on ibutamoren discontinued treatment due to a drug-related AE(49). These findings contrast with a similar randomized, double-blind, placebo controlled trial by Bach et al. that also examined the use of ibutamoren for 6 months in 161 elderly patients recovering from hip fracture. As for how much muscle mass you can gain on MK-677 will depend on many factors, including if you’re stacking it (strongly recommended if you want significant gains) with other compounds. It’s thought that injections of real HGH can decrease fat storage, and as MK-677 functions similarly, we might expect a similar action. There are plenty of other PEDs out there far better suited for pure fat loss! MK-677 should not be considered a fat burner or weight loss compound. For what seems to be quite a simple compound, MK-677 comes with a long list of positive effects. But this is one of the most reliable and promising research chemicals available, with proven results in trials and studies. Ibutamoren is a versatile compound, and we’re still only in the early stages of understanding its full benefits. This mechanism is fundamentally different from that of synthetic growth hormone injections. Although limited work has explored ipamorelin’s effects on hypogonadism specifically, the compound’s interactions with the GI tract are an important factor in determining body fat and overall composition. Ipamorelin led to increases in the sum of the relative fat pad weights compared to the saline-treated controls while GH treatment led to a decrease. The group that started ibutamoren during the second year saw the same changes while the group that switched to placebo in the second year saw a reversal of the changes induced by ibutamoren treatment in the first year. During the first year, ibutamoren resulted in a significant 1.8-fold increase in 24-h mean GH levels and a 1.5-fold increase in serum IGF-1 levels. The original ibutamoren treatment group was separated into either a placebo or continued ibutamoren treatment group. Ibutamoren treatment did not affect FSH and LH levels, but did lead to decreased total testosterone levels with conserved free testosterone levels.
